OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer

BOTHELL, WA, and VANCOUVER, June 24 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI ) announced today that the company has reached an agreement with the U.S. Food and Drug Administration (FDA) via the special protocol assessment process (SPA) on an amendment to the design ...

OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer

Webcast at 7:10 p.m. Eastern Time Today BOTHELL, WA, and VANCOUVER, May 30 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI ) today announced the final results of a Randomized Phase 2 Trial presented during an oral presentation at the American Society of Clinical Oncol...

Prospect Therapeutics, Inc. Assigns All Its Assets to Joseph F. Finn, Jr., C.P.A. for the Benefit of Its Creditors

WELLESLEY HILLS, Mass., May 12 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn"), announced today that assets of Prospect Therapeutics, Inc. ("Prospect") have been assigned to him for the benefit of Prospect's creditors. Prospect's lead product candidate, GCS-100, is a carbohydrate molecu...

Agendia Publishes Direct Evidence That MammaPrint Predicts Benefit of Chemotherapy in Breast Cancer

HUNTINGTON BEACH, California, and AMSTERDAM, February 18 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, today announced that a study demonstrating the direct predictive ability of its breast cancer recurrence test, MammaPrint(R), has been published in Breast Cancer Re...

Adoption of Personalized Medicine May Yield Significant ROI; Time to Achieve Benefit Varies Among U.S. Health Care Stakeholders, According to Deloitte Report

Greatest ROI Opportunity for Consumers in Shortest Period of Time WASHINGTON, Jan. 27 /PRNewswire/ -- As the new administration examines the potential investment in targeted therapies that utilize personalized medicine to improve patient care, a new report released today by the Deloitte Cente...

New Collaboration Aims To Expand Seed-Based Technologies, Benefit Farmers

ST. LOUIS and DURHAM, N.C., Jan. 27 /PRNewswire-FirstCall/ -- As farmers look to get more out of each acre of farmland, St. Louis-based Monsanto (NYSE: MON ) is exploring unique ways to discover and deliver more desirable traits through the seed. Monsanto's new collaboration with GrassRoots ...

Data Presented at Cancer Molecular Markers Meeting Suggests Clinical Benefit for Integrating New Molecular Tests

SUNNYVALE, Calif., Oct. 31 /PRNewswire/ -- Pathwork Diagnostics, a molecular diagnostics company focused on oncology, and City of Hope Hospital presented today the results from a meta-analysis examining the use of immunohistochemistry (IHC) to determine the origin of metastatic cancer at the se...

US College Students Needing TB Testing Now Have the Benefit of QFT(TM)

MELBOURNE, Australia, Aug. 28 /PRNewswire/ -- Students attending US colleges that require tuberculosis (TB) testing will now benefit from interferon-gamma release assays (IGRA) such as QuantiFERON(R)-TB Gold (QFT(TM)), with the release of update TB testing guidelines from the American College ...

Ipsogen Launches MapQuant Dx(TM) Genomic Grade Test to Identify Breast Cancer Patients who Benefit From Chemotherapy

By Improving the Accuracy of Tumor Grading, MapQuant Dx(TM) Genomic Grade Could Spare Tens of Thousands Chemotherapy Treatments per Year ASCO Annual Meeting, May 30, 2008 - booth 23128 CHICAGO, May 30 /PRNewswire/ -- Ipsogen SA (Marseilles, France and New Haven, CT, USA), a cance...

Asthma Patients Not Adequately Controlled on ICS Alone More Likely to Benefit From Advair(R) Than Doubling the Dose of ICS

Findings of Observational Study Presented at American Thoracic Society Annual Meeting RESEARCH TRIANGLE PARK, N.C. and TORONTO, May 20 /PRNewswire/ -- Patients with asthma not adequately controlled on the inhaled corticosteroid fluticasone propionate (FP) alone exp...

New York Benefit to Celebrate Recent Medical Marijuana Successes

A Night of Music & Comedy to Help Push Campaign to Victory May 14, 2008 - Highline Ballroom Spring Soiree to Benefit Effort to Protect Seriously Ill New York Patients Who Use Medical Marijuana NEW YORK, May 13 /PRNewswire/ -- The Marijuana Policy...

Care to Care Begins Providing Radiology Benefit Management Services to Touchstone Health

NEW YORK, Feb. 25 /PRNewswire/ -- Care to Care, a specialty Radiology Benefit Management (RBM) company, announced today that it has signed Touchstone Health HMO Inc. as a client. As a result of this new partnership, Care to Care's client portfolio has grown to over 700,000 lives. (Logo: htt...

Pfizer Animal Health and NTRA Charities Team Up to Benefit the Barbaro Memorial Fund

Promotions Support Fund's Goal of Finding a Cure for Laminitis NEW YORK, Jan. 31 /PRNewswire/ -- Pfizer Animal Health and the National Thoroughbred Racing Association (NTRA) have joined forces to help fund laminitis research through the NTRA Charities - Barbaro Memorial Fund. The partners...

Kosan's Hsp90 Inhibitor, Tanespimycin, Shows 55% Clinical Benefit in Patients With Trastuzumab-Refractory Metastatic Breast Cancer

Five of 20 Evaluable Patients Had Confirmed Partial Responses (25%); Updated Data Presented at San Antonio Breast Cancer Symposium HAYWARD, Calif., Dec. 17 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN ) today announced that its Hsp90 inhibitor, tanespimycin, de...

New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome

PARIS, September 2 /PRNewswire-FirstCall/ -- Sanofi-aventis announced today that one year findings from the landmark ExTRACT-TIMI 25 and STEEPLE studies confirm clear net clinical benefit for patients with acute ST-segment elevation myocardial infarction (STEMI) for Lovenox(R) vs Unfractionnat...

LNA-Based HIF-1 Alpha Inhibitor Shows Early Signs of Clinical Benefit

COPENHAGEN, June 4 /PRNewswire/ -- Santaris Pharma today announced that the cancer drug EZN-2968 - an inhibitor of HIF-1alpha, jointly developed by Enzon Pharmaceuticals and Santaris Pharma A/S - was well tolerated and showed early signs of clinical benefit in previously treated cancer patient...

Physicians benefit from CRM tools

Middleton, Wis. By utilizing targeted direct-mail marketing, Middleton-based Customer Potential Management Group (CPM) has brought a Midwestern health care provider unexpected returns: Forty-six patients for a new primary-care physician, 505 overall new patients and $152,944 net profit. CPM is a...

Heart patients benefit from digital image network

Hartland, Wis. -- The Congenital Heart Institute at Miami Childrens Hospital and Arnold Palmer Hospital are now utilizing VERICIS Cardiovascular Information System. VERCIS, developed by Milwaukee-based Camtronics Medical Systems , streamlines echo images and is designed to improve patient care...

Five ways your company can benefit from patent searches

Did you know there are at least five different types of patent searches you can use to help your company? They include: (1) a search for competitors patents, (2) a clearance search, (3) a patentability search, (4) a right-to-use search and (5) a patent validity search. Each type of search has a dif...

Small businesses to benefit from Business Filings partnership

Sample newsletter Source: Constant Contact MADISON For small businesses, sometimes getting the company name out is a primary concern and Business Filings Incorporated is working to help these fledglings utilize the Internet for marketing. Through a partnership with e-mail marketing compan...

Arizona Pain Specialists Contend Recent Vertebroplasty Studies are Misleading

...icantly better pain reduction than the other treatment groups," noted Dr. Lynch. Several large studies have examined and concluded the clinical benefit and efficacy of vertebroplasty for painful vertebral compression fractures. In 2006, Spine Journal released a systematic review of all available da...

Synthetech Reports First Quarter Fiscal 2010 Results

...ted strength in our biopharmaceutical customer base. In addition, the full benefit of our cost reduction plan implemented in the first quarter begins in the s...d amount of shipments; the resolution of manufacturing difficulties and the benefit of production efficiencies or cost reductions; the impact of the recent eco...

SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights

...tively run fewer samples, make this new offering an ideal system for use in clinical laboratories. OncoCarta Panel - The company continues to benefit from market acceptance of the OncoCarta panel. OncoCarta is a comprehensive multi-gene panel available for profiling rare somatic mutations. It enable...

Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305

...ment to working with our team to create an optimum clinical development plan for our novel drug candidate, CUDC-305, which we believe may offer future benefit to cancer patients," said Dan Passeri, Curis President and Chief Executive Officer. "This transaction is particularly important to Curis because the a...

Repligen Reports First Quarter Fiscal Year 2010 Financial Results

...eat serious diseases and fill an unmet medical need. There are more than 300,000 MRI procedures conducted in the U.S. and Europe each year that could benefit from the use of RG1068. RG2417 for Bipolar Disorder We are currently enrolling a Phase 2b clinical trial of RG2417, an oral formulation of ...

PDI Reports 2009 Second Quarter Financial Results

... years to come. "Finally, I want to note that while we have begun to benefit from the pharmaceutical industry's strategic shift in outsourced sales, the...to the execution of a product commercialization contract and a $2.5 million benefit in 2009 due to a reduction in the loss contract accrual associated with the...

Amicus Therapeutics Announces Second Quarter 2009 Financial Results

... - - - - (1,180) Loss before tax benefit (9,219) (13,623) (16,874) (26,095) (190,978) (Provision for)/ benefit from income taxes (75) - (150) ...

AIAG and MichBio Form New Collaborative Partnership

... quality improvement and apply them in other industries," said J. Scot Sharland, Executive Director, AIAG. Members of both organizations will benefit from shared tools and resources bringing together the best of both manufacturing industries. Through this cooperative relationship AIAG and MichBio h...

Shire plc: Core Portfolio of Products Delivers 20% Sales Growth

... Non GAAP R&D decreased 7% to $118.0 million (2008: $126.8 million). The continued investment in core R&D programs has been offset by the benefit of foreign exchange rates in Q2 2009 over the same period in 2008 and the cessation of certain non-core programs since Q2 2008. As a percentage of pro...

Ceregene Receives Additional Grant From Michael J. Fox Foundation to Expand Long-Term Testing of CERE-120 Patients

...otein family as glial cell-derived neurotrophic factor (GDNF). The two molecules have similar pharmacological properties, and both have been shown to benefit the midbrain dopamine neurons that degenerate in Parkinson's disease. Degeneration of these neurons is responsible for the major motor impairments of...

NxStage Reports Second Quarter 2009 Financial Results

...er guidance for a net loss of $11.5 to $12.5 million. This compares to a net loss of $12.5 million for the second quarter of 2008, which included the benefit of a $2.1 million change in fair value of financial instruments. Cash and cash equivalents as of June 30, 2009 were $24.5 million. The Compa...

Genomic Health Announces Second Quarter 2009 Financial Results and Business Progress

...oss Blue Shield Rhode Island, providing in-network benefit coverage for approximately 680,000 lives. ...tandard measures in helping determine chemotherapy benefit for early-stage breast cancer patients. Onco...en shown to predict the likelihood of chemotherapy benefit as well as recurrence in early-stage breast cancer...

SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2009 FINANCIAL RESULTS

...flavor solutions for a variety of products." The potential market for Senomyx's Sweet Enhancers includes a wide variety of products that would benefit from a reduction in the amount of sugar or sweeteners utilized. Reducing the quantities of sucrose and fructose in products could be advantageous for...

Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University

...stance to HCV polymerase and protease inhibitors. We are rapidly advancing novel small molecule inhibitors of NS4B-RNA binding into the clinic for the benefit of clinicians and HCV patients." "The unique two component nature of the NS4B-RNA target appears to decrease the virus' ability to escape inhib...

Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures

...lt and tedious aspects of such procedures for physicians. Patients may also benefit through reduced surgical times, and therefore reduced time under anesthesia, and health care facilities and payors may also benefit from the potential to reduce operating room time needed, or the total cost ...

ETC Biomedical Announces Chamber Sale in India

...ration, time-honored computerized system. The BARA-MED(R) XD includes O.S.C.A.R. (TM) (Operating System for Control And Recordkeeping), giving you the benefit of patient comfort and safety, plus electronic medical recordkeeping (EMR). With O.S.C.A.R. (TM) on your team, you eliminate the need for opera...

DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD

...Pharma. "Based on data we have already generated in the treatment of acute GI GVHD, we believe that orBec((R) )has the potential to be of significant benefit to cGVHD patients." About Chronic GVHD Graft-versus-Host disease (GVHD) is a major complication of allogeneic hematopoietic cell transpl...

OmniComm Systems Acquires EDC Assets of Leading Phase I Clinical Software Vendor - Logos Technologies, Ltd.

...with OmniComm's eClinical solutions. Our clients, which include Top 10 Pharmaceutical, leading Academic and Clinical Research Organizations, will also benefit from working with a larger global company like OmniComm. " "We are pleased to add the Logos products and operations to the OmniComm team," said...

Yongye International Announces Branded Store Network Increases Over 40% to 5,000 Stores

...he channel," said Mr. Zishen Wu, CEO of Yongye International, Inc. "Our goal is to get the product into the hands of more and more farmers so they can benefit from the use of Shengmingsu and we are accomplishing this. We are confident that the sales of our product will increase as the farmers have the opport...

America's Organic Home-Fueling Movement Begins in Los Angeles

...ry at-home E-Fuel Microfueler™. GreenHouse offers consumers effective home improvement products that not only improve the environment, but also benefit homeowners financially through lower energy bills and reduced maintenance expenses. About E-Fuel The E-Fuel Corporation was founded in 2007 by ...